###begin article-title 0
Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo
###end article-title 0
###begin p 1
###xml 118 126 <span type="species:ncbi:9606">patients</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 1026 1030 <span type="species:ncbi:10090">mice</span>
###xml 1313 1321 <span type="species:ncbi:9606">patients</span>
Recent publications have demonstrated the presence of tissue factor (TF)-bearing microparticles (MPs) in the blood of patients suffering from cancer. However, whether these MPs are involved in thrombosis remains unknown. We show that pancreatic and lung cancer cells produce MPs that express active TF and P-selectin glycoprotein ligand 1 (PSGL-1). Cancer cell-derived MPs aggregate platelets via a TF-dependent pathway. In vivo, cancer cell-derived MPs, but not their parent cells, infused into a living mouse accumulate at the site of injury and reduce tail bleeding time and the time to occlusion of venules and arterioles. This thrombotic state is also observed in mice developing tumors. In such mice, the amount of circulating platelet-, endothelial cell-, and cancer cell-derived MPs is increased. Endogenous cancer cell-derived MPs shed from the growing tumor are able to accumulate at the site of injury. Infusion of a blocking P-selectin antibody abolishes the thrombotic state observed after injection of MPs or in mice developing a tumor. Collectively, our results indicate that cancer cell-derived MPs bearing PSGL-1 and TF play a key role in thrombus formation in vivo. Targeting these MPs could be of clinical interest in the prevention of thrombosis and to limit formation of metastasis in cancer patients.
###end p 1
###begin p 2
###xml 248 263 248 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib49">Trousseau, 1865</xref>
###xml 409 436 409 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">Kakkar and Williamson, 1999</xref>
###xml 438 456 438 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">Stein et al., 2006</xref>
###xml 458 481 458 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">Schiavetti et al., 2008</xref>
###xml 605 623 605 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">Blom et al., 2006b</xref>
###xml 712 729 712 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">Sack et al., 1977</xref>
###xml 731 749 731 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">Blom et al., 2006a</xref>
###xml 904 928 904 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">Neoptolemos et al., 2001</xref>
###xml 1043 1064 1043 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">Prandoni et al., 1992</xref>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 669 677 <span type="species:ncbi:9606">patients</span>
The association between the development of metastasis and the risk of thrombotic complications has been documented since 1865. Armand Trousseau was the first to establish a direct correlation between thrombophlebitis and the development of cancer (Trousseau, 1865). A rather common complication and one of the leading causes of death in patients with cancer is the risk of developing thromboembolic diseases (Kakkar and Williamson, 1999; Stein et al., 2006; Schiavetti et al., 2008). The incidence of thrombosis is high in adenocarcinomas such as ovarian, prostate, lung, and gastrointestinal carcinomas (Blom et al., 2006b), and it is particularly high (up to 57%) in patients suffering from pancreatic cancer (Sack et al., 1977; Blom et al., 2006a). In the latter case, thromboembolic diseases are the second most common cause of mortality, accounting for 44% of total deaths after cancer progression (Neoptolemos et al., 2001). The recurrence of thrombotic complications may also be the first manifestation of underlying malignant disease (Prandoni et al., 1992).
###end p 2
###begin p 3
###xml 468 486 468 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">Gasic et al., 1976</xref>
###xml 488 517 488 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">Sierko and Wojtukiewicz, 2007</xref>
The pathogenesis of the thrombotic state in cancer is associated with the generation of a local and systemic hypercoagulable/thrombotic state that confers a growth advantage to tumor cells. It is now known that activation of the coagulation cascade and aggregation of blood platelets around cancer cells protects the cells from the different degradative pathways present in the blood, and also facilitates dissemination of cancer cells to various sites of metastasis (Gasic et al., 1976; Sierko and Wojtukiewicz, 2007). This supports a model in which the presence of tissue factor (TF), generation of thrombin, and activation of platelets favor the aggressive biology of cancer. Nevertheless, the cause of this association remains unclear.
###end p 3
###begin p 4
###xml 134 150 134 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Kim et al., 2003</xref>
###xml 152 174 152 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Del Conde et al., 2007</xref>
###xml 176 195 176 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">Tilley et al., 2008</xref>
###xml 447 465 443 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">Ghosh et al., 2008</xref>
###xml 553 578 549 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">Abid Hussein et al., 2003</xref>
###xml 807 826 803 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">M&#252;ller et al., 2003</xref>
###xml 967 986 963 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">Tilley et al., 2008</xref>
###xml 1032 1054 1028 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Del Conde et al., 2007</xref>
###xml 1056 1073 1052 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Hron et al., 2007</xref>
###xml 1075 1097 1071 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">Tesselaar et al., 2007</xref>
###xml 1265 1282 1261 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Hron et al., 2007</xref>
###xml 1284 1304 1280 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">Zwicker et al., 2007</xref>
###xml 1306 1325 1302 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">Langer et al., 2008</xref>
###xml 1354 1371 1350 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Hron et al., 2007</xref>
###xml 1373 1395 1369 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">Tesselaar et al., 2007</xref>
###xml 1412 1431 1408 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">Dvorak et al., 1981</xref>
###xml 1448 1467 1444 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Falati et al., 2003</xref>
###xml 1469 1487 1465 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Myers et al., 2003</xref>
###xml 1489 1513 1485 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">Vandendries et al., 2007</xref>
###xml 1595 1598 1587 1590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IIb</sub>
###xml 1602 1603 1591 1592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1612 1613 1597 1598 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</sub>
###xml 1617 1618 1599 1600 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1952 1971 1934 1953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Falati et al., 2003</xref>
###xml 1973 1997 1955 1979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">Vandendries et al., 2007</xref>
###xml 945 953 <span type="species:ncbi:9606">patients</span>
###xml 999 1007 <span type="species:ncbi:9606">patients</span>
###xml 1789 1794 <span type="species:ncbi:10090">mouse</span>
Different reports suggest a potential role for circulating microparticles (MPs) in the establishment of a thrombotic state in cancer (Kim et al., 2003; Del Conde et al., 2007; Tilley et al., 2008). MPs are defined as cell-derived membrane fragments and range in size from 0.1 to 1 microm in diameter. They are characterized by their presence at the surface of negative phospholipid moieties that are essential for initiation of blood coagulation (Ghosh et al., 2008); they also bear at least one of the antigenic markers distinctive of the parent cell (Abid Hussein et al., 2003). Aggregated platelets, leukocytes, erythrocytes, and endothelial lineages constitute the most important sources of circulating MPs under many pathophysiological situations, including thrombosis, inflammation, and angiogenesis (Muller et al., 2003). Recent clinical studies have shown that the concentration of circulating TF-bearing MPs is significantly greater in patients with cancer (Tilley et al., 2008), including patients with pancreatic cancer (Del Conde et al., 2007; Hron et al., 2007; Tesselaar et al., 2007), suggesting that these MPs may be responsible for the thrombotic state associated with cancers. Meanwhile, the cellular origins of such MPs have not been determined (Hron et al., 2007; Zwicker et al., 2007; Langer et al., 2008) and may include platelets (Hron et al., 2007; Tesselaar et al., 2007), cancer cells (Dvorak et al., 1981), or monocytes (Falati et al., 2003; Myers et al., 2003; Vandendries et al., 2007). At their surface, platelet-derived MPs express activated integrins (e.g., alphaIIbbeta3 or alphavbeta3) and receptors (i.e., GPVI and GPIb-IX-V) known to be involved in thrombus formation. Monocyte-derived MPs that have been isolated, labeled, and infused into a recipient mouse accumulate at the site of a laser-induced injury by binding to P-selectin expressed on activated platelets through P-selectin glycoprotein ligand 1 (PSGL-1; Falati et al., 2003; Vandendries et al., 2007). To date, no study has determined the role of cancer cell-derived MPs in thrombus formation in vivo.
###end p 4
###begin p 5
###xml 508 513 <span type="species:ncbi:10090">mouse</span>
In the present study, we hypothesize that cancer cell-derived MPs bearing PSGL-1 are involved in the development of a thrombotic state. We demonstrate that pancreatic cancer cells are able to produce MPs in vitro that express active TF and PSGL-1. We show that cancer cell-derived MPs circulate in the bloodstream and accumulate at the site of injury in a P-selectin-dependent manner in vivo. Finally, we observe that cancer cell-derived MPs, but not their parental cells, accelerate thrombus formation in a mouse model of cancer.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin title 7
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 10 15 <span type="species:ncbi:10090">mouse</span>
Human and mouse pancreatic and lung cancer cell lines are able to shed MPs that express TF and PSGL-1 in vitro
###end title 7
###begin p 8
###xml 400 408 396 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 495 512 491 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Haas et al., 2006</xref>
###xml 514 534 510 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">Khorana et al., 2007</xref>
###xml 655 663 651 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 768 776 764 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 981 1000 977 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Falati et al., 2003</xref>
###xml 1002 1020 998 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">Myers et al., 2003</xref>
###xml 1120 1128 1116 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 1172 1180 1168 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 1370 1378 1366 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 120 125 <span type="species:ncbi:10090">mouse</span>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
###xml 1469 1474 <span type="species:ncbi:10090">mouse</span>
To determine whether pancreatic or lung cancer cells could shed MPs, ultracentrifuged supernatants of human (SOJ-6) and mouse (Panc02) adenocarcinoma pancreatic cell lines or mouse Lewis lung carcinoma cancer cell lines (LLC1) were evaluated by flow cytometry. All cancer cell lines produced vesicles ranging in size from 0.4 to 1 microm in diameter, and these particles were able to bind annexin V (Fig. 1 A). Previous reports have shown that TF is present on the surface of cancer cell lines (Haas et al., 2006; Khorana et al., 2007). Accordingly, we observed that SOJ-6, Panc02, and LLC1 cancer cells express TF on their surface by immunofluorescence (Fig. 1 B). TF was also detected by Western blotting of lysates obtained from pancreatic cancer cell-derived MPs (Fig. 1 C). Identical results were obtained with all other pancreatic adenocarcinoma (BxPC-3) and carcinoma (MiaPaCa-2, PANC-1, and LLC1) cell lines studied. Monocyte-derived MPs have been shown to express PSGL-1 (Falati et al., 2003; Myers et al., 2003). Double labeling with annexin V as a positive control revealed that Panc02 and LLC1 cancer cells (Fig. 2 A), as well as Panc02- and LLC1-derived MPs (Fig. 2 B), express PSGL-1 but not P-selectin (not depicted) on their surface. PSGL-1 was also detected by Western blotting in lysates obtained from pancreatic cancer cell- and monocyte-derived MPs (Fig. 2 C). In contrast, no signal was detected by flow cytometry analysis or Western blotting when mouse fibroblast-derived MPs (L929 cell lines) were studied. We conclude that pancreatic and lung cancer cells can shed MPs that constitutively express active TF and PSGL-1.
###end p 8
###begin p 9
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pancreatic and lung cancer cell lines shed MPs that express TF in vitro.</bold>
Pancreatic and lung cancer cell lines shed MPs that express TF in vitro. (A) Flow cytometry analysis showing annexin V-FITC labeling of SOJ-6, Panc02, and LLC1 cell-derived MPs. Negative controls were realized without addition of calcium. (B) Immunofluorescence microscopy of cancer cells using an anti-TF antibody. (C) Western blot analysis of protein extracts from SOJ-6-derived MPs with a specific anti-TF antibody. All of the experiments were independently performed three times.
###end p 9
###begin p 10
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pancreatic and lung cancer cell&#8211;derived MPs express PSGL-1.</bold>
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Pancreatic and lung cancer cell-derived MPs express PSGL-1. (A) Immunofluorescence microscopy of SOJ-6, Panc02, and LLC1 cells with an antibody directed against PSGL-1 and an Alexa Fluor 488-conjugated secondary antibody. Incubation with the secondary antibody alone served as a negative control. (B) Flow cytometric analysis of J774 (C+), L929 (C-), Panc02-, and LLC1-derived MPs labeled both with annexin V-FITC and with an anti-PSGL-1 PE-conjugated antibody. PSGL-1+ MPs are represented by the black histogram. Negative controls were obtained by excluding calcium from the annexin V labeling and in the presence of an irrelevant PE-conjugated IgG (gray histogram). (C) Western blot analysis of Panc02-derived MPs (Panc02 MPs) and J774 (C+) and L929 (C-) cells with a specific anti-PSGL-1 antibody. All of the experiments were independently performed three times.
###end p 10
###begin title 11
Cancer cell-derived MPs, but not their parental cells, modulate thrombus formation in vivo
###end title 11
###begin p 12
###xml 129 130 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 141 161 141 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Dubois et al., 2006b</xref>
###xml 486 487 486 487 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 603 604 603 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 615 623 615 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 732 740 732 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 910 911 906 907 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1056 1064 1052 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 1152 1160 1148 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 1358 1366 1350 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 1915 1923 1907 1915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 2296 2304 2288 2296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 2455 2482 2447 2474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Panicot-Dubois et al., 2007</xref>
###xml 2603 2604 2595 2596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2620 2621 2612 2613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2801 2802 2793 2794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2852 2853 2844 2845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2903 2904 2895 2896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2910 2918 2902 2910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 3160 3168 3152 3160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 67 71 <span type="species:ncbi:10090">mice</span>
###xml 450 455 <span type="species:ncbi:10090">mouse</span>
###xml 664 668 <span type="species:ncbi:10090">mice</span>
###xml 793 798 <span type="species:ncbi:10090">mouse</span>
###xml 829 834 <span type="species:ncbi:10090">mouse</span>
###xml 1243 1248 <span type="species:ncbi:10090">mouse</span>
###xml 1280 1285 <span type="species:ncbi:10090">mouse</span>
###xml 1796 1801 <span type="species:ncbi:10090">mouse</span>
###xml 2037 2041 <span type="species:ncbi:10090">mice</span>
###xml 2158 2162 <span type="species:ncbi:10090">mice</span>
###xml 2228 2232 <span type="species:ncbi:10090">mice</span>
###xml 2588 2592 <span type="species:ncbi:10090">mice</span>
###xml 2755 2759 <span type="species:ncbi:10090">mice</span>
###xml 2820 2824 <span type="species:ncbi:10090">mice</span>
###xml 2873 2877 <span type="species:ncbi:10090">mice</span>
###xml 3056 3061 <span type="species:ncbi:10090">mouse</span>
We have previously described the kinetics of thrombus formation in mice after an injury induced by topical application of an FeCl3 solution (Dubois et al., 2006b). To determine the involvement of MPs in thrombus formation in vivo, experiments we performed using a fibered fluorescent microscope that allows for real-time in vivo imaging after excitation at 660 nm. We examined thrombus formation induced by exposure of the adventitial surface of the mouse mesenteric vessels to 10% FeCl3 for 5 min. Under these conditions, platelets began to accumulate in injured vessels between 5 and 15 min after FeCl3 exposure (Fig. 3 A). Only three out of the eight wild-type mice studied formed occlusive thrombi during the 35-min experiment (Fig. 3 B). When Panc02 cancer cell-derived MPs (0.2 microg/g/mouse corresponding to 18,000 MPs/g/mouse) were infused into the bloodstream 5 min before topical application of FeCl3, platelets began to accumulate 1-5 min after induction of the injury, leading to occlusion of the arterioles between 3 and 10 min after injury (Fig. 3 A). The median time to occlusion of the arteriole in this condition was 6 min (P < 0.01; Fig. 3 B). Similar results were observed after infusion of LLC1-derived MPs (0.08 microg/g/mouse, corresponding to 18,000 MPs/g/mouse), with a median time to occlusion of the arteriole of 12 min (P < 0.05; Fig. 3 B). The median time to arteriole occlusion was significantly shorter than the median time to occlusion observed without infusion of MPs (P < 0.05). These results indicate that infusion of cancer cell-derived MPs affected the kinetics of thrombus formation. To determine whether cancer cells may also be involved in thrombus formation, we determined the time to occlusion in arterioles after infusion of cancer cells (5,000 cells/g/mouse, equivalent to the maximum concentration of cells that may be infused without altering blood flow; not depicted; Fig. 3 A). In this condition, no statistical difference was found in comparison with the kinetics observed when wild-type mice were injured. Indeed, platelet accumulation was detected between 5 and 10 min after injury. Only three out of seven mice studied after infusion of Panc02 cells and only one out of eight mice studied after infusion of LLC1 cells formed occlusive thrombi (Fig. 3 B). To confirm the involvement of cancer cell-derived MPs in thrombus formation, tail bleeding time experiments were performed as previously described (Panicot-Dubois et al., 2007). After injection with Panc02- and LLC1-derived MPs, the median tail bleeding time observed in wild-type mice was 63 s (n = 8) and 79 s (n = 7), respectively. These values were significantly lower (P < 0.01) than the bleeding times (close to 150 s) obtained for wild-type mice that were not infused with cells or MPs (n = 13), wild-type mice infused with Panc02 cells (n = 8), or wild-type mice infused with LLC1 cells (n = 8; Fig. 3 C). We next determined the number of MPs sufficient enough to affect kinetics of thrombosis. We observed that an amount as low as 0.2 ng/g/mouse of cancer cell-derived MPs significantly accelerated kinetics of thrombosis in vivo in our model (Fig. 3 D). Collectively, these results indicate that infusion of cancer cell-derived MPs, but not infusion of their parental cells, accelerates thrombus growth in vivo, suggesting that cancer cell-derived MPs may participate in thrombus formation.
###end p 12
###begin p 13
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cancer cell&#8211;derived MPs accelerate thrombus formation in vivo.</bold>
###xml 512 513 504 505 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 785 786 777 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 861 862 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 914 915 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 954 955 946 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 995 996 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1081 1082 1073 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1143 1144 1135 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1182 1183 1174 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1209 1210 1201 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1237 1238 1229 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1316 1317 1308 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1447 1448 1439 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1492 1493 1484 1485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1541 1542 1533 1534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 269 274 <span type="species:ncbi:10090">mouse</span>
###xml 345 350 <span type="species:ncbi:10090">mouse</span>
###xml 398 403 <span type="species:ncbi:10090">mouse</span>
###xml 446 451 <span type="species:ncbi:10090">mouse</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
###xml 823 827 <span type="species:ncbi:10090">mice</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 933 937 <span type="species:ncbi:10090">mice</span>
###xml 973 977 <span type="species:ncbi:10090">mice</span>
###xml 1014 1018 <span type="species:ncbi:10090">mice</span>
###xml 1075 1079 <span type="species:ncbi:10090">mice</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
###xml 1105 1109 <span type="species:ncbi:10090">mice</span>
###xml 1149 1153 <span type="species:ncbi:10090">mice</span>
###xml 1188 1192 <span type="species:ncbi:10090">mice</span>
###xml 1215 1219 <span type="species:ncbi:10090">mice</span>
###xml 1243 1247 <span type="species:ncbi:10090">mice</span>
###xml 1310 1314 <span type="species:ncbi:10090">mice</span>
###xml 1337 1341 <span type="species:ncbi:10090">mice</span>
###xml 1360 1364 <span type="species:ncbi:10090">mice</span>
###xml 1440 1445 <span type="species:ncbi:10090">mouse</span>
###xml 1466 1470 <span type="species:ncbi:10090">mice</span>
###xml 1485 1490 <span type="species:ncbi:10090">mouse</span>
###xml 1511 1515 <span type="species:ncbi:10090">mice</span>
###xml 1534 1539 <span type="species:ncbi:10090">mouse</span>
###xml 1561 1565 <span type="species:ncbi:10090">mice</span>
Cancer cell-derived MPs accelerate thrombus formation in vivo. Thrombus formation was assessed after infusion of Alexa Fluor 660-conjugated anti-CD41 antibody into wild-type mice in the presence of Panc02-derived MPs (MPs Panc02, 0.2 microg of MP-associated proteins/g/mouse), LLC1-derived MPs (MPs LLC1, 0.08 microg of MP-associated proteins/g/mouse), or Panc02 cells (Cells Panc02, 5,000 cells/g/mouse) or LLC1 cells (Cells LLC1, 5,000 cells/g/mouse). Injury of the mesenteric vessels was induced with 10% FeCl3 for 5 min. (A) Representative composite images of fluorescence depicting thrombus formation of labeled platelet accumulation (white) on mesenteric vessels (Pre, before injury). (B) Time to vessel occlusion reported in minutes for mesenteric arterioles in wild-type mice (n = 10 thrombi in 10 mice), wild-type mice infused with Panc02-derived MPs (n = 10 thrombi in 7 mice), or with LLC1-derived MPs (n = 6 thrombi in 6 mice), Panc02 cells (n = 7 thrombi in 7 mice), or LLC1 cells (n = 8 thrombi in 8 mice). (C). Bleeding time in seconds determined in wild-type mice (n = 13 mice), wild-type mice infused with Panc02-derived MPs (n = 8 mice), or with LLC1-derived MPs (n = 7 mice), Panc02 cells (n = 8 mice), or LLC1 cells (n = 8 mice). (D) Times to arteriole occlusion were observed in wild-type mice (n = 10 thrombi in 10 mice) and in wild-type mice infused with different concentrations of Panc02-derived MPs (MPs 0.02 ng/g/mouse, n = 7 thrombi in 6 mice; MPs 0.2 ng/g mouse, n = 7 thrombi in 7 mice; and MPs 200 ng/g mouse, n = 10 thrombi in 9 mice). Horizontal bars indicate median values. Experiments were independently performed 10 times (A and B) and at least six times (C and D). **, P < 0.01; *, P < 0.05.
###end p 13
###begin p 14
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 488 510 488 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">Willekens et al., 2005</xref>
###xml 674 682 674 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 800 819 800 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dubois et al., 2007</xref>
###xml 821 848 821 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Panicot-Dubois et al., 2007</xref>
###xml 1181 1189 1177 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 1278 1279 1274 1275 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1504 1512 1500 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 184 189 <span type="species:ncbi:10090">mouse</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 483 486 <span type="species:ncbi:10116">rat</span>
###xml 942 947 <span type="species:ncbi:10090">mouse</span>
###xml 979 984 <span type="species:ncbi:10090">mouse</span>
###xml 1037 1042 <span type="species:ncbi:10090">mouse</span>
###xml 1088 1093 <span type="species:ncbi:10090">mouse</span>
To determine whether cancer cell-derived MPs accumulate at the site of FeCl3-induced injury in vivo, MPs were isolated, labeled with the DiD fluorochrome, and infused into a recipient mouse. First, we determined the half-life of exogenous MPs in the blood circulation of healthy mice (Fig. 4 A). The results show that 50% of exogenous MPs were eliminated from the blood circulation in <15 min, confirming the results previously described for erythrocyte-derived MPs infused into the rat (Willekens et al., 2005). After infusion of exogenous MPs and induction of a chemical injury to mesenteric arterioles, a fluorescent signal corresponding to DiD-labeled MPs was detected (Fig. 4 B). This accumulation of cancer cell-derived MPs at the site of injury was further confirmed by intravital microscopy (Dubois et al., 2007; Panicot-Dubois et al., 2007). Using such a system, we simultaneously imaged DiO-labeled cancer-derived MPs (0.2 microg/g/mouse, corresponding to 18,000 MPs/g/mouse) and DiD-labeled cancer cells (5,000 Panc02 cells/g/mouse) infused into the bloodstream of a recipient mouse. Both cancer cell-derived MPs and cancer cells were detected circulating in the blood (Fig. 4 C). However, only cancer cell-derived MPs were found to accumulate at the site of the FeCl3-induced injury. 8 min after injury, the number of exogenous MPs accumulating at the site of injury increased, indicating that thrombus-associated MPs remained in the animal for a longer time period than did circulating MPs (Fig. 4 C). We conclude that cancer cell-derived MPs, but not their parental cells, accumulate at the site of injury in vivo and accelerate thrombus growth.
###end p 14
###begin p 15
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cancer cell&#8211;derived MPs accumulate at the site of injury in mice.</bold>
###xml 159 160 159 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 562 563 560 561 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 152 157 <span type="species:ncbi:10090">mouse</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 413 418 <span type="species:ncbi:10090">mouse</span>
###xml 649 653 <span type="species:ncbi:10090">mice</span>
###xml 813 818 <span type="species:ncbi:10090">mouse</span>
###xml 889 894 <span type="species:ncbi:10090">mouse</span>
###xml 941 946 <span type="species:ncbi:10090">mouse</span>
###xml 1196 1200 <span type="species:ncbi:10090">mice</span>
Cancer cell-derived MPs accumulate at the site of injury in mice. (A) Half-life of DiO-labeled Panc02-derived MPs in the blood circulation of a healthy mouse (n = 4 mice, performed independently) reported as the mean +/- SD. (B) Imaging of DiD-labeled Panc02-derived MPs using fibered fluorescence microscopy. Panc02-derived MPs were labeled with DiD (left) before infusion into the blood circulation of a living mouse. Although no fluorescent signal was detected in the microcirculation before injury (middle), MPs were detected accumulating at the site of FeCl3-induced injury (right). Images are representative of six injuries performed in three mice, independently. (C) Intravital videomicroscopy visualization of mesenteric vessels. DiO-labeled MPs (depicted in green; 0.2 microg of MP-associated proteins/g/mouse) and their DiD-labeled parental cells (depicted in red; 5,000 cells/g/mouse) were simultaneously infused into a recipient mouse. Circulating MPs and cells were detected in the microcirculation before injury (second from left). Note that no fluorescent signal was detected before infusion of MPs and cells (left). The experiment was independently performed three times in three mice.
###end p 15
###begin title 16
###xml 42 46 <span type="species:ncbi:10090">mice</span>
Characterization of a thrombotic state in mice developing ectopic tumors
###end title 16
###begin p 17
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 456 457 456 457 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 500 501 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 505 506 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 562 569 562 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table I</xref>
###xml 642 643 642 643 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1719 1726 1707 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table I</xref>
###xml 1832 1838 1820 1826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 828 832 <span type="species:ncbi:10090">mice</span>
###xml 890 894 <span type="species:ncbi:10090">mice</span>
###xml 995 999 <span type="species:ncbi:10090">mice</span>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
###xml 1463 1467 <span type="species:ncbi:10090">mice</span>
###xml 1495 1499 <span type="species:ncbi:10090">mice</span>
###xml 1713 1717 <span type="species:ncbi:10090">mice</span>
###xml 1950 1954 <span type="species:ncbi:10090">mice</span>
###xml 1982 1986 <span type="species:ncbi:10090">mice</span>
###xml 2081 2085 <span type="species:ncbi:10090">mice</span>
###xml 2151 2155 <span type="species:ncbi:10090">mice</span>
###xml 2201 2205 <span type="species:ncbi:10090">mice</span>
Next, we created a mouse model of cancer induced by subcutaneous injection of pancreatic (Panc02) or lung cancer (LLC1) cells. 5 wk after induction of the ectopic tumor, the number of endogenous circulating MPs in both healthy mice and mice developing tumors were compared by flow cytometry analysis. To characterize the cellular origin of MPs, we first labeled MPs using antibodies specific for platelets (CD41+), erythrocytes (TER 119+), leukocytes (CD45+), cells likely of endothelial origin (CD31+CD41-), and cancer cells (MUC-1+). The data are presented in Table I (see also ). As expected, the number of endogenous circulating annexin V+ MPs was significantly increased in mice developing tumors in comparison with control mice (median = 9,383 MPs/microl and 10,018 MPs/microl of plasma for Panc02- and LLC1-induced-tumor mice, respectively, and 8,951 MPs/microl of plasma in control mice; P < 0.05). The amount of platelet- and endothelial cell-derived MPs was significantly increased in mice developing tumors in comparison with control mice. However, neither the number of leukocyte-derived circulating MPs nor the quantity of endogenous erythrocyte-derived MPs increased in comparison with the control. We also addressed the presence of endogenous circulating cancer cell-derived MPs using Muc-1, a protein that is highly expressed in various epithelial cancers. As expected, the amount of Muc-1-bearing MPs was significantly increased in tumor-induced mice in comparison with healthy mice. We also detected MPs bearing the carbohydrate CA19-9, which is highly expressed in lung and pancreatic cancers. Of note, this antigen was only present on MPs in blood obtained from Panc02- and LLC1-tumor-induced mice (Table I). Because we have previously observed that Panc02- and LLC1-derived MPs express PSGL-1 on their surface (Fig. 2) and because the quantity of leukocyte-derived MPs, which also bear PSGL-1, was not increased in tumor-induced mice in comparison with control mice, we determined the quantity of circulating PSGL-1-bearing MPs in the different populations of mice. The number of MPs bearing PSGL-1 was significantly increased in mice developing tumors in comparison with healthy mice. Collectively, our results indicate that the elevation of endogenous cell-derived MPs positive for annexin V results from a selective increase in MPs originating from platelets, endothelial cells, and tumor cells.
###end p 17
###begin p 18
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 46 48 46 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Number and cellular origins of MPs (x106/liter-1 plasma) in healthy and cancer mice
###end p 18
###begin p 19
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Differences between mice developing a pancreatic cancer and healthy mice.
###end p 19
###begin p 20
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Differences between mice developing a lung cancer and healthy mice.
###end p 20
###begin p 21
###xml 240 248 240 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 310 311 310 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 400 408 400 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 488 496 488 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 521 529 521 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
###xml 973 974 973 974 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1057 1065 1057 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 1071 1074 1071 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">5 C</xref>
###xml 1079 1087 1079 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 C</xref>
###xml 1093 1096 1093 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">5 A</xref>
###xml 1209 1217 1209 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
###xml 659 663 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 927 931 <span type="species:ncbi:10090">mice</span>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
###xml 1282 1286 <span type="species:ncbi:10090">mice</span>
###xml 1405 1409 <span type="species:ncbi:10090">mice</span>
Tail bleeding times were significantly reduced in mice developing a tumor (median times for mice that received Panc02 or LLC1 cancer cells were 70 and 78 s, respectively) in comparison with mice that did not (median time = 150 s; P < 0.01; Fig. 5 A). We determined the kinetics of thrombus formation after FeCl3 injury to both the mesenteric arterioles and venules of control and tumor-bearing mice (Fig. 5 B). A significant decrease in the time to occlusion of the arterioles (P < 0.05; Fig. 5 C) and venules (P < 0.05; Fig. 5 D) was observed in mice developing tumors (a median time to occlusion of 8 and 15 min in arterioles and 13 and 8 min in venules in mice developing Panc02- and LLC1-induced tumors, respectively) in comparison with control mice (median time > 35 and 18 min in arterioles and venules, respectively). Interestingly, the tail bleeding time and time to occlusion of arterioles and venules were similar in mice developing tumors (median volume = 239 mm3) and mice for which Panc02-derived MPs were infused into the circulation (compare Fig. 3 B with 5 C and Fig. 3 C with 5 A). Furthermore, we did not observe any linear correlation between the volume of the tumor and the bleeding time (Fig. 5 E). Our results indicate that the presence of an ectopic tumor in mice increases the quantity of MPs present in the bloodstream and accelerates thrombus formation, as compared with healthy mice.
###end p 21
###begin p 22
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Characterization of a thrombotic state in mice developing tumors.</bold>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 298 299 298 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 598 599 598 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 861 862 861 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 956 957 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1146 1147 1146 1147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1179 1180 1179 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1253 1254 1253 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 102 106 <span type="species:ncbi:10090">mice</span>
###xml 113 117 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 259 263 <span type="species:ncbi:10090">mice</span>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 1069 1074 <span type="species:ncbi:10090">mouse</span>
###xml 1173 1177 <span type="species:ncbi:10090">mice</span>
Characterization of a thrombotic state in mice developing tumors. Kinetics of thrombosis in wild-type mice or in mice developing Panc02-derived (Cancer Panc02) or LLC1-derived (Cancer LLC1) tumors. (A) Bleeding times were determined in wild-type mice (n = 13 mice), mice developing a Panc02 tumor (n = 11 mice), or mice developing an LLC1 tumor (n = 6 mice). (B) Thrombus formation was studied after infusion of Alexa Fluor 660-conjugated anti-CD41 Fab fragment and Syto 62 in wild-type mice and in mice developing tumors. Injury was induced in mesenteric vessels by topical application of 10% FeCl3 for 5 min. Representative fluorescence images depicting the kinetics of thrombus formation of labeled platelet accumulation (white) on mesenteric arterioles (Pre, before injury). (C and D) Time to vessel occlusion reported in minutes for mesenteric arterioles (n = 13, 7, and 6 thrombi for WT, Cancer Panc02, and Cancer LLC1, respectively; C) and venules (n = 13, 11, and 6 thrombi for WT, Cancer Panc02, and Cancer LLC1, respectively; D). One injury was performed per mouse. (E) Bleeding times (in seconds) in function of the tumor volume (in mm3) in Panc02 tumor-bearing mice (n = 11). The linear coefficient of determination value is represented by R2. Horizontal bars in A, C, and D indicate median values. Experiments were independently performed at least six times (A-D) and 11 times (E). **, P < 0.01; *, P < 0.05.
###end p 22
###begin title 23
Endogenous cancer-derived MPs accumulate at the site of thrombus formation in vivo
###end title 23
###begin p 24
###xml 422 423 422 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 905 913 905 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 1397 1405 1397 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 1580 1600 1580 1600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">Dubois et al., 2006a</xref>
###xml 1602 1621 1602 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dubois et al., 2007</xref>
###xml 1947 1955 1943 1951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 C</xref>
###xml 2013 2021 2009 2017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 2045 2053 2041 2049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 D</xref>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
###xml 673 677 <span type="species:ncbi:10090">mice</span>
###xml 947 951 <span type="species:ncbi:10090">mice</span>
###xml 2317 2321 <span type="species:ncbi:10090">mice</span>
To determine if cancer cells and/or MPs shed during tumor growth could participate and influence thrombus formation in vivo, an ectopic tumor was induced by injection of Panc02 cells labeled with quantum dots (Qdots). Using this compound, we were able to detect fluorescence in vitro for more than a week in cultured cells and in MPs shed from the cells (unpublished data). 1 wk after injection of Qdot-labeled cells, FeCl3 injury was administered to the mesentery of the mouse. The presence of Panc02 cells and/or MPs at the site of injection, in the circulation, and at the site of injury was followed by in vivo imaging. As expected, when Qdots alone were injected into mice, a fluorescent signal was detected 1 wk later only at the site of injection. In contrast, Qdot-labeled cells and/or MPs were detected at the site of injection and in the circulation, and also accumulated at the site of injury (Fig. 6 A). These results indicate that in mice developing ectopic tumors, cancer cells and/or cancer-derived MPs may reach the bloodstream and accumulate at the site of injury, suggesting that these MPs may influence the kinetics of thrombus growth. To discriminate between Panc02 cells and endogenous Panc02-derived MPs (produced by the tumor in contrast with MPs prepared in vitro and infused into the bloodstream), we stably transfected Panc02 cells with the pEGFP-N1 vector encoding GFP (Fig. 6 B). 5 wk after subcutaneous injection of Panc02 cells overexpressing GFP, the presence and accumulation of a fluorescent signal before and after injury induced by a dye laser (Dubois et al., 2006a; Dubois et al., 2007) were detected in the cremaster microcirculation using the intravital microscope. Particles were observed, ranging in size from 0.4 (the minimum size we were able to detect using our system) to 1 microm (the maximum size measured for detected particles), that were likely endogenous MPs circulating in the blood circulation (Fig. 6 C) and accumulating at the site of injury in both venules (Fig. 6 D, left) and arterioles (Fig. 6 D, right). Together with our previous results showing that Panc02-derived MPs but not Panc02 cells accumulate at the site of injury, we conclude that Panc02-derived MPs shed from a growing tumor circulate in the bloodstream and participate in thrombus formation in mice.
###end p 24
###begin p 25
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Endogenous cancer cell&#8211;derived MPs accumulate at the site of thrombus formation in vivo.</bold>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 366 367 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 514 515 514 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 215 220 <span type="species:ncbi:10090">mouse</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 603 608 <span type="species:ncbi:10090">mouse</span>
###xml 1004 1008 <span type="species:ncbi:10090">mice</span>
Endogenous cancer cell-derived MPs accumulate at the site of thrombus formation in vivo. (A) Qdot-labeled Panc02 cells (2 x 106 cells) or Qdots alone (Control) were injected subcutaneously into the right flank of a mouse. 1 wk later, fluorescent signals were detected at the site of injection (left), and in the mesentery before (middle panel) and after (right) FeCl3-induced injury. (B) Fluorescence microscopy of Panc02 cells overexpressing GFP before subcutaneous injection into wild-type mice. (C and D) 2 x 105 Panc02 cells overexpressing GFP were injected subcutaneously into the right flank of a mouse. 5 wk later, the cremaster was isolated and fluorescent circulating GFP-labeled MPs were detected in the blood microcirculation (red arrow, direction of the blood flow; red circle, GFP microparticle; C) and accumulating at the site of injury in venules (D, left) and arterioles (D, right). All images are representative of three independent experiments observed for nine thrombi formed in three mice.
###end p 25
###begin title 26
Endogenous cancer-derived MPs accumulate at the site of injury by binding to P-selectin and accelerate thrombus growth in a TF-dependent pathway
###end title 26
###begin p 27
###xml 73 81 73 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 A</xref>
###xml 120 128 120 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 B</xref>
###xml 143 151 143 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 C</xref>
###xml 336 342 336 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 578 597 578 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">Milsom et al., 2007</xref>
###xml 599 626 599 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">Pawlinski and Mackman, 2008</xref>
###xml 720 722 720 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 786 788 786 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 D</xref>
###xml 919 921 919 921 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 934 936 934 936 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 1262 1270 1254 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 D</xref>
###xml 1480 1488 1472 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 E</xref>
###xml 1653 1661 1645 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 E</xref>
###xml 278 283 <span type="species:ncbi:10090">mouse</span>
###xml 745 750 <span type="species:ncbi:10090">mouse</span>
###xml 803 808 <span type="species:ncbi:9606">human</span>
The thrombotic effects of cancer cell-derived MPs on tail bleeding time (Fig. 7 A) and time to occlusion of arterioles (Fig. 7 B) and venules (Fig. 7 C) were significantly decreased when proteins at the surface of MPs were stripped by trypsin before infusion into the recipient mouse. Cancer cells and MPs express TF on their surfaces (Fig. 1). To determine whether TF was present in a decrypted (active) form on the surface of cancer cells and MPs, the activity of TF present on SOJ-6, Panc02, and LLC1 cells, as well as MPs, was determined. As previously described by others (Milsom et al., 2007; Pawlinski and Mackman, 2008), we observed that cancer cells express active TF, demonstrating activity ranging from 7 x 10-4 pmol/cell for the two mouse cancer cell lines tested to 17 x 10-4 pmol/cell for human SOJ-6 cancer cells (Fig. 7 D). All MPs studied expressed similar concentrations of active TF (between 2.3 x 10-4 and 4.3 x 10-4 pmol/MP). We then determined the activity of TF as a ratio of TF concentration to surface area to control for the difference in size between a cancer cell (diameter = 20 microm) and an MP (diameter = 1 microm). Results obtained show that the density of active TF is increased >100-fold in MPs as compared with cancer cells. (Fig. 7 D). These cancer cell-derived MPs were able to activate platelets and to induce platelet aggregation and formation of a fibrin mesh after addition of platelet-poor plasma (PPP) to a washed platelet preparation (Fig. 7 E). This effect was slightly inhibited when a fibrinogen-deficient plasma was added to the platelet preparation and was abolished by using a factor VII-depleted PPP (Fig. 7 E). These data demonstrate that MPs activate and aggregate platelets via a TF-dependent pathway in vitro.
###end p 27
###begin p 28
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Endogenous cancer-derived MPs accelerate thrombus growth through a TF-dependent pathway.</bold>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 478 479 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 600 601 600 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 762 764 762 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 776 778 776 778 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 799 800 799 800 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 866 867 864 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 121 125 <span type="species:ncbi:10090">mice</span>
###xml 199 204 <span type="species:ncbi:10090">mouse</span>
###xml 230 234 <span type="species:ncbi:10090">mice</span>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
###xml 279 283 <span type="species:ncbi:10090">mice</span>
###xml 365 369 <span type="species:ncbi:10090">mice</span>
###xml 499 503 <span type="species:ncbi:10090">mice</span>
###xml 868 873 <span type="species:ncbi:9606">human</span>
Endogenous cancer-derived MPs accelerate thrombus growth through a TF-dependent pathway. (A-C) Kinetics of thrombosis in mice perfused with control Panc02 MPs or trypsinized Panc02 MPs (18,000 MPs/g/mouse) compared with wild-type mice. (A) Bleeding time of wild-type mice and of mice perfused with control MPs (WT+MPs) or trypsinized MPs (WT+trypsinized MPs; n = 6 mice for each group). Time to vessel occlusion reported in minutes for mesenteric arterioles (B) and venules (C; n = 6 thrombi in six mice for each group). Injury of the mesenteric vessels was induced by topical application of 10% FeCl3 for 5 min. Horizontal bars indicate median values. **, P < 0.01; *, P < 0.05. (D) Measurement of TF activity on the surface of cancer cells and MPs in pmol/cell-1 and pmol/MP-1 (left) or in pmol/mm2 (right), reported as the mean +/- SD. (E) Aggregation of 2.5 x 108 human washed platelets/ml induced by addition of thrombin (Curve 1, red), SOJ-6 MPs (1 microg of MP-associated proteins/ml) in the absence (Curve 2, black) or presence of 5% vol/vol (final) of PPP (Curve 3, blue), factor VII-depleted PPP (Curve 4, green), or fibrinogen-deficient PPP (Curve 5, gray). Experiments were independently performed six times (A-C) and three times (D and E).
###end p 28
###begin p 29
###xml 328 347 328 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Falati et al., 2003</xref>
###xml 349 373 349 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib50">Vandendries et al., 2007</xref>
###xml 449 450 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 467 475 467 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 A</xref>
###xml 638 646 638 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 A</xref>
###xml 1107 1115 1107 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 B</xref>
###xml 1130 1138 1130 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 C</xref>
###xml 1442 1450 1442 1450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig8">Fig. 8 D</xref>
To determine whether endogenous MPs arising from cancer cells accumulate in the thrombus growth via an interaction between PSGL-1 and P-selectin, the accumulation of endogenous Panc02-derived MPs was compared at the site of injury before and after infusion of a blocking P-selectin monoclonal antibody, as previously described (Falati et al., 2003; Vandendries et al., 2007). Although accumulation of endogenous MPs was observed after laser- or FeCl3-induced injury (Fig. 8 A, left) to the mesentery, no signal corresponding to endogenous cancer cell-derived MPs bound to a thrombus was detected upon infusion of the P-selectin antibody (Fig. 8 A, right). The same results were observed when exogenous DiD-labeled cancer cell-derived MPs were infused into the circulation in the presence of blocking antibody (unpublished data). We conclude that cancer cell-derived MPs accumulate at the site of thrombus formation via interactions between the PSGL-1 expressed at their surface and P-selectin expressed on activated platelets and endothelial cells. Furthermore, the median times to occlusion in arterioles (Fig. 8 B) and venules (Fig. 8 C) were significantly higher when cancer cell-derived MPs were infused in the presence of blocking P-selectin antibody than when they were infused alone (P < 0.05). These results were confirmed by determining the tail bleeding time, which was significantly higher in the presence of P-selectin (P < 0.01; Fig. 8 D). Collectively, our results indicate that tumor-shed MPs reach the bloodstream, accumulate at the site of injury in a P-selectin-dependent manner, and accelerate thrombus growth mainly via a TF-dependent pathway.
###end p 29
###begin p 30
###xml 0 93 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Endogenous cancer-derived MPs accelerate thrombus formation in a P-selectin&#8211;dependent manner.</bold>
###xml 104 105 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 404 405 404 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 976 977 968 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 991 992 983 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1015 1016 1007 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1034 1035 1026 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1066 1067 1058 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1108 1109 1100 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1123 1124 1115 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1147 1148 1139 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1165 1166 1157 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1197 1198 1189 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1302 1303 1294 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1317 1318 1309 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1341 1342 1333 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1359 1360 1351 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1391 1392 1383 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 193 198 <span type="species:ncbi:10090">mouse</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 570 575 <span type="species:ncbi:10090">mouse</span>
###xml 613 618 <span type="species:ncbi:10090">mouse</span>
###xml 756 760 <span type="species:ncbi:10090">mice</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 1448 1453 <span type="species:ncbi:10090">mouse</span>
Endogenous cancer-derived MPs accelerate thrombus formation in a P-selectin-dependent manner. (A) 2 x 105 Panc02 cells overexpressing GFP were injected subcutaneously into the right flank of a mouse. 5 wk later, chemical injury of the mesentery was induced, and fluorescence was detected in the absence (left, Control) or presence of circulating P-selectin blocking antibody (right, P-selectin antibody; n = 6 thrombi in three mice). (B-D). Kinetics of thrombosis in wild-type mice, wild-type mice infused with Panc02 MPs (WT+MPs, 0.2 microg of MP-associated proteins/g/mouse), or with Panc02 MPs plus 2 microg/g/mouse of anti P-selectin blocking antibody (WT+MPs+anti P-sel). Controls were performed by infusion of anti-P-selectin antibody into wild-type mice (WT+anti P-sel) or by infusing an irrelevant antibody into wild-type mice perfused with MPs (WT+MPs+Irr Ab). Injury of the mesenteric vessels was chemically induced, and the time to vessel occlusion for arterioles (n = 10 for WT, n = 7 for WT+anti Psel, n = 10 for WT+MPs, n = 7 for WT+MPs+anti Psel, and n = 8 for WT+MPs+Irr Ab; B) and veinules (n = 13 for WT, n = 7 for WT+anti Psel, n = 7 for WT+MPs, n = 7 for WT+MPs+anti Psel, and n = 8 for WT+MPs+Irr Ab; C) was measured. (D) Bleeding times were determined for all conditions studied (n = 13 for WT, n = 7 for WT+anti Psel, n = 8 for WT+MPs, n = 6 for WT+MPs+Anti Psel, and n = 8 for WT+MPs+Irr Ab). One thrombus was performed per mouse. Horizontal bars designate median values. Experiments were independently performed three times (A) and at least seven times (B-D). **, P < 0.01; *, P < 0.05.
###end p 30
###begin title 31
DISCUSSION
###end title 31
###begin p 32
###xml 291 295 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 325 329 <span type="species:ncbi:10090">mice</span>
###xml 507 512 <span type="species:ncbi:10090">mouse</span>
In the present paper, we studied the role of cancer cell-derived MPs in thrombus formation. To characterize the thrombotic/coagulation state in vivo, we measured the kinetics of thrombus formation after a chemical- or laser-induced injury. We also compared the tail bleeding time of healthy mice, mice developing tumors, and mice after infusion of cancer cells and MPs. Our results indicate that pancreatic and lung cancer cells are able to shed MPs expressing TF and PSGL-1 on their surface. In vivo, in a mouse model of cancer, these MPs circulate in the blood, accumulate at the site of injury in a P-selectin-dependent manner, and may participate in the generation of thrombin, likely via the expression of active TF at their surface. The presence of MPs is necessary for the formation of a thrombotic state in vivo. Finally, our results show that cancer cells do not accumulate at the site of injury and do not accelerate the kinetics of thrombosis in our model. To our knowledge, this is the first study to use imaging of endogenous cancer cell-derived MPs and cancer cells to characterize their respective roles in the kinetics of thrombus formation in vivo.
###end p 32
###begin p 33
###xml 254 275 254 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">Riewald and Ruf, 2001</xref>
###xml 277 294 277 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">Haas et al., 2006</xref>
###xml 296 317 296 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">Versteeg et al., 2008</xref>
###xml 487 508 487 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Furie and Furie, 2006</xref>
###xml 769 785 769 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">Kim et al., 2003</xref>
###xml 787 809 787 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Del Conde et al., 2007</xref>
###xml 811 831 811 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">Zwicker et al., 2007</xref>
###xml 1361 1376 1361 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">Yu et al., 2005</xref>
###xml 1378 1397 1378 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">Davila et al., 2008</xref>
###xml 1511 1519 1511 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 2024 2041 2024 2041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">Hron et al., 2007</xref>
###xml 2043 2065 2043 2065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">Tesselaar et al., 2007</xref>
###xml 2328 2347 2328 2347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">Piccin et al., 2007</xref>
###xml 3229 3250 3229 3250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">Furie and Furie, 2006</xref>
###xml 3530 3549 3530 3549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">Combes et al., 1999</xref>
###xml 3551 3573 3551 3573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">Chamouard et al., 2005</xref>
###xml 3715 3735 3715 3735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">Lacroix et al., 2007</xref>
###xml 674 682 <span type="species:ncbi:9606">patients</span>
###xml 1250 1254 <span type="species:ncbi:10090">mice</span>
###xml 1799 1803 <span type="species:ncbi:10090">mice</span>
###xml 2205 2209 <span type="species:ncbi:10090">mice</span>
###xml 2250 2254 <span type="species:ncbi:10090">mice</span>
###xml 2441 2449 <span type="species:ncbi:9606">patients</span>
###xml 2450 2454 <span type="species:ncbi:10090">mice</span>
Among the different proteins able to activate and aggregate platelets while simultaneously favoring the process of metastasis, TF expressed on cancer cells has been suggested to play a key role in the development of a cancer-associated thrombotic state (Riewald and Ruf, 2001; Haas et al., 2006; Versteeg et al., 2008). However, no direct correlation could be established between the presence of TF on cancer cells and the development of thrombosis complications associated with cancer (Furie and Furie, 2006), suggesting that other important mechanisms may link cancer and thrombosis. Recently, various reports have shown that the number of circulating MPs is increased in patients developing different types of cancers known to be associated with a thrombotic state (Kim et al., 2003; Del Conde et al., 2007; Zwicker et al., 2007). These observations suggest that MPs may play a key role in the development of the thrombotic complications associated with cancer. Our results indicate that MPs derived from cancer cells enhance thrombus formation. The presence of PSGL-1 targets MPs to sites of thrombosis, whereas active TF actively participates in the formation of the thrombus by generating thrombin and fibrin. Two recent reports have shown, in mice models, a direct correlation between the size of a tumor and the level of TF present in cell-free plasma (Yu et al., 2005; Davila et al., 2008). We did not observe such correlation when comparing the bleeding time associated with the volume of the tumors (Fig. 5 E). Indeed, even relatively small tumors are sufficient enough to strongly diminish the tail bleeding time and the occlusion time in our model. These results confirm that the presence in the bloodstream of few tumor-derived MPs is sufficient enough to induce a thrombotic state in mice. Last, in the two papers, authors have not discriminated the origin of circulating TF that may come from platelets or monocyte-derived MPs. Other studies have previously shown that such MPs may originate from platelets (Hron et al., 2007; Tesselaar et al., 2007). In this study, we observed that the quantities of circulating platelet-, endothelial cell-, and cancer cell-derived MPs are increased in mice developing tumors compared with healthy mice. With the knowledge that platelets release MPs only when they aggregate (Piccin et al., 2007), it not surprising that the amount of circulating MPs derived from platelets increases when patients/mice develop a thrombotic state. Indeed, this pathological state leads to the activation and aggregation of platelets, either directly via cancer cells or indirectly via production of thrombin by TF. Therefore, it is likely that platelet-derived MPs are a consequence of thrombotic complications and do not cause the development of this phenotype. However, platelet-derived MPs, when present in the blood, may also participate in the stability of a thrombotic state associated with cancer. Endothelial cells activated by tumoral MPs may provide a supplementary procoagulant surface by TF exposure. Although several reports have shown that TF is expressed on cancer cells, there is conflicting evidence as to the presence of this factor at the surface of platelets and their MPs (Furie and Furie, 2006). To our knowledge, this is the first paper to demonstrate an increase in circulating endothelial cell-derived MPs in association with cancer. However, previous publications have shown that the level of endothelial cell-derived MPs is increased in inflammatory-related diseases (Combes et al., 1999; Chamouard et al., 2005). These MPs, by expressing proteins such as metalloproteases, urokinase plasminogen activator, and urokinase plasminogen activator receptor (Lacroix et al., 2007), may potentially take part in and amplify the processes of inflammation, angiogenesis, and fibrinolysis. Further experiments are needed to determine the actual role of platelet-derived MPs in concert with cancer cell- and endothelial cell-derived MPs.
###end p 33
###begin p 34
###xml 372 380 372 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 716 735 716 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Falati et al., 2003</xref>
###xml 909 928 909 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">Kaplan et al., 2006</xref>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
When cancer cells and cancer cell-derived MPs were infused into the circulation of a living mouse, only MPs were observed to accumulate at the site of a laser- or chemical-induced injury, suggesting that cancer cells may not participate in thrombus formation. These cells were not eliminated from the blood, because we were able to detect them circulating in the vessels (Fig. 4 C, before injury). This result was confirmed by our data showing that injection of cancer cells did not influence either the kinetics of thrombus formation or bleeding times. Our results are consistent with previous observations showing that monocyte-derived MPs, but not their parent cells, may indeed interact with a growing thrombus (Falati et al., 2003). Although circulating cancer cells did not bind to the site of injury, they may interact with the endothelium at sites of premetastatic niches to form sites of metastasis (Kaplan et al., 2006). Different hypotheses may explain why MPs and not their parental cells bind to a growing thrombus. It is possible that this interaction occurs via the negative phospholipid moieties commonly expressed on the surface of MPs. Furthermore, the quantity and density of binding partners present, such as PSGL-1, may be more important for MPs than for their parent cells. This point is illustrated by our results showing that even if the activity of cell TF was greater than that of the MP, when the results were reported per surface unit, the activity of TF was >100-fold higher in MPs than in cells. This result may also explain why the cells were not thrombogenic compared with MPs. In our conditions, Panc02-derived MPs have a more dramatic effect on thrombosis in arterioles compared with venules, whereas LLC1-derived MPs have the opposite effect. This tendency may be caused, at least partially, by the levels of active TF expressed by Panc02- and LLC1-derived MPs. Indeed, activation of the coagulation cascade resulting in thrombin generation is known to play a more important role in thrombus formation induced in arteries than in veins.
###end p 34
###begin p 35
###xml 327 347 327 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">Falati et al. (2003)</xref>
###xml 598 599 598 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 807 808 807 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1164 1186 1164 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">Del Conde et al., 2007</xref>
###xml 1558 1566 1558 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 D</xref>
###xml 1700 1708 1700 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 E</xref>
###xml 1887 1898 1887 1898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, A&#8211;C</xref>
###xml 2476 2491 2476 2491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">Ni et al., 2003</xref>
###xml 2740 2767 2740 2767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Panicot-Dubois et al., 2007</xref>
###xml 617 621 <span type="species:ncbi:10090">mice</span>
###xml 1118 1126 <span type="species:ncbi:9606">patients</span>
###xml 2992 3000 <span type="species:ncbi:9606">patients</span>
We demonstrated that PSGL-1 is present on the surface of MPs and showed that injection of a P-selectin blocking antibody prevents the accumulation of MPs at the site of injury and reduces thrombus formation. The P-selectin-PSGL-1 axis has previously been described as being involved in the binding of MPs to platelets. Indeed, Falati et al. (2003) have previously shown that exogenous monocyte-derived MPs express PSGL-1 and bind to a growing thrombus in a P-selectin-dependent manner in a laser injury model. We determined that inhibition of P-selectin did not affect time to occlusion in the FeCl3 model in healthy mice, showing that accumulation of monocyte-derived MPs by the P-selectin-PSGL-1 axis may have a minor implication when cancer-derived MPs are not involved in thrombus formation after a FeCl3-induced injury. Our results identify P-selectin as a potentially good pharmaceutical target for the prevention of thrombosis associated with cancer, and may also explain why heparin, which binds to and blocks selectin, is much more effective than warfarin, a vitamin K antagonist, in preventing thrombosis in patients suffering from Trousseau's syndrome (Del Conde et al., 2007). MPs also express negatively charged phospholipids on their surface that may participate with TF in activation of the coagulation cascade. However, based on our results, the activity of TF seems to be critical for the generation of thrombin. Indeed, we found that (a) in vitro TF activity per surface unit is 100-fold more important in MPs than in their parental cells (Fig. 7 D), (b) the use of factor VII-deficient plasma abolishes the effect of MPs on platelet aggregation and the formation of a fibrin mesh (Fig. 7 E), and (c) in vivo hydrolysis of the surface proteins but not the negatively charged phospholipids present on MPs completely abrogated their effect on the kinetics of thrombosis (Fig. 7, A-C). Based on our results, we propose a two-step mechanism to describe the involvement of cancer cell-derived MPs in thrombosis. First, MPs bind to the site of injury by interactions between PSGL-1 and P-selectin present on activated platelets and endothelial cells. Second, MPs affect thrombus formation, likely via the expression of active TF on their surface. Other proteins and lipids may also be of importance in this process. Among the different proteins expressed by cancer cell-derived MPs, fetoacinar pancreatic protein and fibronectin were identified (unpublished data; Ni et al., 2003). Both of these may play an important role in thrombus formation. Fetoacinar pancreatic protein, an onco-isoform of bile salt-dependent lipase, increases the kinetics of thrombus formation by binding to CXCR4 on the surface of activated platelets (Panicot-Dubois et al., 2007). Overall, our data provide a new molecular basis for establishing relationships between cancer and thrombosis, and may facilitate the development of new pharmaceutical drugs designed to prevent thrombosis and metastasis in patients suffering from cancer.
###end p 35
###begin title 36
MATERIALS AND METHODS
###end title 36
###begin title 37

###end title 37
###begin title 38
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice.
###end title 38
###begin p 39
###xml 19 23 <span type="species:ncbi:10090">mice</span>
Wild-type C57BL/6J mice were obtained from Janvier. All animal care and experimental procedures were performed as recommended by the European Community guidelines and approved by the local ethical committee of the Universite de la Mediterranee and the French Ministry of Agriculture (agreement no. 13.382).
###end p 39
###begin title 40
Antibodies and reagents.
###end title 40
###begin p 41
###xml 1474 1475 1470 1471 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1646 1647 1642 1643 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1719 1720 1715 1716 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
###xml 253 258 <span type="species:ncbi:9606">Human</span>
###xml 308 313 <span type="species:ncbi:9940">sheep</span>
###xml 319 324 <span type="species:ncbi:9606">human</span>
###xml 355 361 <span type="species:ncbi:9986">Rabbit</span>
###xml 367 372 <span type="species:ncbi:10090">mouse</span>
###xml 424 427 <span type="species:ncbi:10116">rat</span>
###xml 433 438 <span type="species:ncbi:10090">mouse</span>
###xml 464 467 <span type="species:ncbi:10116">rat</span>
###xml 473 478 <span type="species:ncbi:10090">mouse</span>
###xml 503 506 <span type="species:ncbi:10116">rat</span>
###xml 512 517 <span type="species:ncbi:10090">mouse</span>
###xml 544 547 <span type="species:ncbi:10116">rat</span>
###xml 553 558 <span type="species:ncbi:10090">mouse</span>
###xml 587 590 <span type="species:ncbi:10116">rat</span>
###xml 596 601 <span type="species:ncbi:10090">mouse</span>
###xml 619 622 <span type="species:ncbi:10116">rat</span>
###xml 639 644 <span type="species:ncbi:10090">mouse</span>
###xml 677 680 <span type="species:ncbi:10116">rat</span>
###xml 697 702 <span type="species:ncbi:10090">mouse</span>
###xml 777 780 <span type="species:ncbi:10116">rat</span>
###xml 785 790 <span type="species:ncbi:10090">mouse</span>
###xml 1002 1005 <span type="species:ncbi:10116">rat</span>
###xml 1088 1094 <span type="species:ncbi:9793">donkey</span>
###xml 1100 1103 <span type="species:ncbi:10116">rat</span>
###xml 1105 1111 <span type="species:ncbi:9793">donkey</span>
###xml 1117 1120 <span type="species:ncbi:10116">rat</span>
###xml 1138 1144 <span type="species:ncbi:9793">donkey</span>
###xml 1150 1155 <span type="species:ncbi:9940">sheep</span>
###xml 1177 1183 <span type="species:ncbi:9793">donkey</span>
###xml 1189 1195 <span type="species:ncbi:9986">rabbit</span>
###xml 1859 1864 <span type="species:ncbi:58664">Iroko</span>
Rat monoclonal anti-mouse CD41 antibody (clone MWReg30) was obtained from Emfret. Fab fragments for the anti-CD41 antibody were generated by using the immunopure Fab preparation kit from Thermo Fisher Scientific, and then conjugated to Alexa Fluor 660. Human alpha-thrombin, factor VII-deficient plasma, and sheep anti-human TF were obtained from Biopep. Rabbit anti-mouse TF was purchased from American Diagnostica Inc. PE rat anti-mouse CD41 (clone MWReg30), PE rat anti-mouse CD45 (clone 30-F11), PE rat anti-mouse CD31 (clone MEC 13.3), PE rat anti-mouse TER-119 (clone TER-119), PE rat anti-mouse PSGL-1, blocking rat monoclonal anti-mouse P-selectin (clone RB40.34), and rat monoclonal anti-mouse PSGL-1 (clone 4RA10) antibodies, and FITC-annexin V, PE-annexin V, and PE rat and mouse isotype controls were obtained from BD. Monoclonal anti-CA19.9 and anti-MUC-1-core glycoprotein antibodies were purchased from Novocastra Laboratories and were conjugated in house to Alexa Fluor 488. Irrelevant rat immunoglobulins were purchased from BD and SouthernBiotech. Peroxydase-conjugated donkey anti-rat, donkey anti-rat-Alexa Fluor 488, donkey anti-sheep-Alexa Fluor 488, and donkey anti-rabbit-Alexa Fluor 594 antibodies; Vybrant DiD and DiO cell-labeling solutions; the Qtracker 705 cell labeling kit; Alexa Fluor 594 and Alexa Fluor 660 antibody-labeling kits; Syto 62, Lipofectamine 2000, PLUS reagent, RPMI 1640, DMEM, and OptiMEM media; and penicillin, streptomycin, l-glutamine, trypsin-EDTA, nonenzymatic cell dissociation solution, and fungizone were obtained from Invitrogen. Megamix beads were purchased from BioCytex. Prostaglandin I2 was obtained from EMD. BSA, apyrase grade VI, Gly-Pro-Arg-Pro, and FeCl3 were purchased from Sigma-Aldrich. pEGFP-N1 vector was obtained from Clontech Laboratories, Inc. Tirofiban (Aggrastat) was purchased from Iroko Pharmaceuticals.
###end p 41
###begin title 42
Cell lines and culture conditions.
###end title 42
###begin p 43
###xml 60 78 60 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">Fujii et al., 1990</xref>
###xml 255 276 255 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">Corbett et al. (1984)</xref>
###xml 516 540 516 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">Bertram and Janik (1980)</xref>
###xml 1075 1076 1075 1076 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 1225 1226 1215 1216 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 107 112 <span type="species:ncbi:10090">mouse</span>
###xml 369 375 <span type="species:ncbi:3635">cotton</span>
###xml 452 457 <span type="species:ncbi:10090">mouse</span>
###xml 654 659 <span type="species:ncbi:10090">mouse</span>
###xml 816 821 <span type="species:ncbi:10090">mouse</span>
###xml 843 848 <span type="species:ncbi:10090">mouse</span>
One cell line from human pancreatic adenocarcinomas (SOJ-6; Fujii et al., 1990), and two cell lines from a mouse pancreatic adenocarcinoma (Panc02) and a Lewis lung carcinoma (LLC1) were studied. The Panc02 cell line has been established and described by Corbett et al. (1984). In brief, it is derived from a pancreatic ductal adenocarcinoma induced by implantation of cotton thread-carrying 3-methyl-cholanthrene into the pancreas tissue of a C57BL/6 mouse. The LLC1 cell line has been established and described by Bertram and Janik (1980) and was obtained from the American Type Culture Collection. It is derived from a Lewis lung carcinoma of a C57BL mouse strain. The Panc02 cell line was provided by E. Beraud (Institut National de la Sante et de la Recherche Medicale [INSERM] UMR911, Marseille, France). L929 mouse fibroblasts and J774 mouse macrophages were provided by F. Levy (INSERM UMR608, Marseille, France). SOJ-6, LLC1, L929, and J774 cells were grown in DMEM medium, and Panc02 cells were grown in RPMI 1640 medium. Media were supplemented with 10% FCS, 2 mM l-glutamine, 100 U/ml penicillin, 100 microg/ml streptomycin, and 0.1% fungizone. Cells were grown at 37degreesC in a humidified atmosphere with 5% CO2.
###end p 43
###begin title 44
Transfection.
###end title 44
###begin p 45
###xml 197 224 197 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">Panicot-Dubois et al., 2004</xref>
Panc02 cells were stably transfected with the pEGFP-N1 plasmid using Lipofectamine 2000 and PLUS reagent according to the manufacturer's recommendations. Cells were cloned as previously described (Panicot-Dubois et al., 2004).
###end p 45
###begin title 46
Isolation of MPs.
###end title 46
###begin p 47
###xml 38 61 38 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">Berckmans et al. (2001)</xref>
###xml 183 184 183 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 374 393 374 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">Dignat-George, 2006</xref>
###xml 326 330 <span type="species:ncbi:10090">Mice</span>
The isolation of MPs was adapted from Berckmans et al. (2001). In brief, cells at 80% of confluency were incubated for 15 h in OptiMEM medium. MP-rich medium was centrifuged at 1,500 g to eliminate cellular debris and ultracentrifuged at 20,000 g to isolate MPs. The final pellet containing MPs was resuspended in 0.5 ml PBS. Mice MPs were isolated as previously described (Dignat-George, 2006). L929 and J774 cells were activated with 10 ng/ml TNF-alpha before MP isolation. Concentrations of MPs were determined by protein quantification using the bicinchoninic acid assay (Thermo Fisher Scientific).
###end p 47
###begin title 48
PAGE and Western blotting.
###end title 48
###begin p 49
###xml 171 198 171 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Panicot-Dubois et al., 2007</xref>
SDS-PAGE performed on gels of polyacrylamide (7.5% acrylamide in the presence of 0.1% sodium dodecyl sulfate) and Western blotting were performed as previously described (Panicot-Dubois et al., 2007).
###end p 49
###begin title 50
Flow cytometry.
###end title 50
###begin p 51
###xml 74 95 74 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">Sabatier et al., 2002</xref>
###xml 808 827 774 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">Robert et al., 2009</xref>
###xml 302 307 <span type="species:ncbi:10090">mouse</span>
Platelet-free plasma (PFP) samples were prepared as previously described (Sabatier et al., 2002) using serial centrifugations and stored at -80degreesC until use. For MP labeling, 30 microl of freshly thawed PFP or of the MP suspension was incubated for 30 min with 10 microl FITC-annexin V or PE-anti-mouse monoclonal antibodies (30 microg/ml anti-CD41, 40 microg/ml anti-TER-119, 40 microg/ml anti-CD45, 40 microg/ml anti-CD31, or 50 microg/ml anti-PSGL-1). Concentration-matched PE-isotype antibodies (IgG1, clone R3-34; IgG2a, clone R35-95; IgG2b, clone A95-1) or annexin V-FITC with phosphate-buffered saline without calcium were used as control. Analyses were performed on a flow cytometer (Cytomics FC500; Beckman Coulter) using a Megamix bead-calibrated protocol (BioCytex), as previously described (Robert et al., 2009). Flow-Count fluorospheres (Beckman Coulter) were added to each sample to express MP counts as absolute numbers.
###end p 51
###begin title 52
Fluorescence microscopy.
###end title 52
###begin p 53
Cells were grown up to 80% confluence on an 8-chamber glass slide system (Thermo Fisher Scientific), washed with PBS, and fixed for 30 min at 4degreesC in PBS containing 2% paraformaldehyde. Once fixed, cells were blocked for 1 h at 4degreesC with 1% BSA in PBS buffer. Cells were then incubated at 4degreesC with the appropriate dilution of antibodies, followed by incubation with an Alexa Fluor 488- or Alexa Fluor 594-conjugated secondary antibody. Between each step, cells were exhaustively rinsed with PBS and were observed on a microscope (Axiovert 200; Carl Zeiss, Inc.).
###end p 53
###begin title 54
TF activity assays.
###end title 54
###begin p 55
###xml 701 706 <span type="species:ncbi:10090">mouse</span>
A chromogenic assay (Actichrome TF; American Diagnostica Inc.) was used to analyze TF activity. TF activity was measured in cell or MP suspension according to the manufacturer's instructions. Cells or MPs were incubated in the presence of factors VIIa and X. The reagents were incubated at 37degreesC for complex formation to convert factor X to factor Xa, and the amount of Xa generated was measured by its ability to cleave a chromogenic substrate, spectrozyme Xa. Absorbance was read at 405 nm with a microplate reader (MR5000; Dynatech). TF concentration was determined by interpolation of a standard curve obtained from different amounts of lipidated TF standards. For TF activity measurement in mouse plasma, a TF/TF pathway inhibitor-depleted plasma was added to the reaction mixture of lipidated TF standards, and DeltaA405-490 was measured to calculate TF concentration.
###end p 55
###begin title 56
Platelet aggregation studies.
###end title 56
###begin p 57
###xml 56 75 56 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">Dubois et al., 2004</xref>
###xml 86 87 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 358 377 352 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dubois et al., 2007</xref>
Washed platelets were obtained as previously described (Dubois et al., 2004). 2.5 x 108 washed platelets/ml were stirred at 37degreesC for 10 min in 2 x 4-channel aggregometers (Apact 4004; LABiTec). Positive controls were performed in the presence of 1 U/ml thrombin. The extent of platelet aggregation was defined as the percent change in optical density (Dubois et al., 2007).
###end p 57
###begin title 58
MP half-life.
###end title 58
###begin p 59
###xml 51 55 <span type="species:ncbi:10090">mice</span>
The carotid arteries and jugular veins of 8-wk-old mice were cannulated. DiO-labeled MPs were infused in the bloodstream via the jugular veins. Blood samples were collected in sodium citrate (3.2%, 1:2 vol/vol) via the carotid artery catheter before MP injection and 5, 15, 30, 45, and 60 min after injection.
###end p 59
###begin title 60
Induction of ectopic tumor.
###end title 60
###begin p 61
###xml 343 344 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 365 366 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
###xml 439 443 <span type="species:ncbi:10090">mice</span>
For all in vivo experiments, tumor cells in the exponential growth phase were briefly exposed to nonenzymatic cell dissociation buffer to dislodge the cells. They were next carefully washed, resuspended in PBS, and diluted to the desired cell number/inoculum. 3-wk-old C57BL/6 mice were injected subcutaneously into the right flank with 2 x 105 Panc02 cells, 2 x 105 LLC1 cells, 2 x 106 Panc02-labeled cells, or with PBS alone for control mice. Cells were labeled with Qdots (Qtraker 705), DiD, or DiO according to the manufacturer's instructions (Invitrogen).
###end p 61
###begin title 62
Intravital microscopy.
###end title 62
###begin p 63
###xml 492 512 486 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dubois et al. (2007)</xref>
###xml 580 599 574 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dubois et al., 2007</xref>
###xml 601 628 595 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">Panicot-Dubois et al., 2007</xref>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 339 344 <span type="species:ncbi:10090">mouse</span>
###xml 392 397 <span type="species:ncbi:10090">mouse</span>
Mice were anesthetized with an intraperitoneal injection of 100 mg/kg ketamine and 12.5 mg/kg Xylazine (Bayer). The jugular vein was cannulated to maintain anesthesia by injection of 50 mg/kg pentobarbital injection and to infuse antibodies, cells, and MPs as needed. The trachea was intubated to facilitate spontaneous respiration by the mouse, and a thermocontrolled blanket maintained the mouse at 37degreesC. Cremaster and mesentery preparations were performed as previously described by Dubois et al. (2007). Intravital videomicroscopy was performed as previously described (Dubois et al., 2007; Panicot-Dubois et al., 2007). Data were obtained using a microscope (BX61WI; Olympus) with a 60 x 0.9 or a 20 x 0.5 NA water immersion objective. Alternatively, a fibered fluorescence microscopy imaging system (Cellvizio; Mauna Kea Technologies) was used to image platelets. The optical probe used in this study has a tip diameter of 4.2 mm (MiniO/100; Mauna Kea Technologies), providing images below the surface of biological tissue and at a depth 100 +/- 5 microm, with a lateral resolution of 1.8 microm.
###end p 63
###begin title 64
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
FeCl3-induced injury.
###end title 64
###begin p 65
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 137 157 137 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Dubois et al., 2006b</xref>
###xml 246 247 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 320 340 320 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Dubois et al., 2006b</xref>
###xml 445 450 <span type="species:ncbi:10090">mouse</span>
###xml 642 647 <span type="species:ncbi:10090">mouse</span>
The FeCl3-induced model of thrombosis has been shown to cause substantial damage to the endothelium and exposure of underlying collagen (Dubois et al., 2006b). Vessel injuries were generated by using a 1 x 2-mm filter paper soaked with a 10% FeCl3 solution and placed over the vessel for 5 min, as previously described (Dubois et al., 2006b). Platelet accumulation at the site of injury was detected by infusion in blood circulation of 250 ng/g/mouse of anti-CD41 Fab fragment coupled with Alexa Fluor 660 for 35 min or until blood flow cessation lasted for >10 s (occlusion). Typically, one venous and one arterial injury were performed per mouse.
###end p 65
###begin title 66
Laser-induced injury.
###end title 66
###begin p 67
###xml 223 243 223 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">Dubois et al., 2006b</xref>
###xml 245 264 245 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dubois et al., 2007</xref>
Vessel-wall injuries were induced with a nitrogen dye laser (Micropoint; Photonics Instruments) focused through the microscope objective, parfocal with the focal plane and aimed at the vessel wall, as previously described (Dubois et al., 2006b; Dubois et al., 2007). Typically, one or two pulses were required to induce vessel wall injury.
###end p 67
###begin title 68
Tail bleeding time.
###end title 68
###begin p 69
###xml 90 109 90 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">Dubois et al., 2007</xref>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Tail bleeding times were performed as previously described on anesthetized 8-wk-old mice (Dubois et al., 2007).
###end p 69
###begin title 70
Statistics.
###end title 70
###begin p 71
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Significance was determined by a paired two-tailed Student's t test for the in vitro experiments and by Wilcoxon's rank-sum test for the in vivo experiments. The difference was considered significant at P < 0.05.
###end p 71
###begin title 72
Online supplemental material.
###end title 72
###begin p 73
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 52 53 52 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 123 130 123 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table I</xref>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows the box plot distribution of CD31+CD41- MPs and TER119+ MPs in healthy and tumor-bearing mice (data are from Table I). Online supplemental material is available at .
###end p 73
###begin title 74
Supplementary Material
###end title 74
###begin title 75
[Supplemental Material]
###end title 75
###begin p 76
The authors are indebted to L. Arnaud for the quantification of MPs. The authors are grateful to J. Varin, J. Courageot, and C. Prevot for expert technical assistance, and to M.-C. Alessi for the use of the aggregometers. The authors thank P.-A. Dancer, B. Brisson, J. Rebouillat, A. Hembury, and Mauna Kea Technologies for the use of the Cellvizio fibered fluorescence microscopy imaging system.
###end p 76
###begin p 77
This work was supported by institutional funding from INSERM and Aix-Marseille Universite. This work was supported by the Association pour la Recherche sur le Cancer (grant ARC-1038 to C. Dubois).
###end p 77
###begin p 78
The authors have no conflicting financial interests.
###end p 78
###begin article-title 79
Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo.
###end article-title 79
###begin article-title 80
###xml 49 55 <span type="species:ncbi:9606">humans</span>
Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation.
###end article-title 80
###begin article-title 81
Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture.
###end article-title 81
###begin article-title 82
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.
###end article-title 82
###begin article-title 83
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study.
###end article-title 83
###begin article-title 84
Circulating cell-derived microparticles in Crohn's disease.
###end article-title 84
###begin article-title 85
###xml 89 97 <span type="species:ncbi:9606">patients</span>
In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.
###end article-title 85
###begin article-title 86
###xml 112 116 <span type="species:ncbi:10090">mice</span>
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.
###end article-title 86
###begin article-title 87
Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation.
###end article-title 87
###begin article-title 88
Microvesicle-associated tissue factor and Trousseau's syndrome.
###end article-title 88
###begin article-title 89
Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry.
###end article-title 89
###begin article-title 90
Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation.
###end article-title 90
###begin article-title 91
Real time in vivo imaging of platelets during thrombus formation.
###end article-title 91
###begin article-title 92
Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo.
###end article-title 92
###begin article-title 93
Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model.
###end article-title 93
###begin article-title 94
Tumor shedding and coagulation.
###end article-title 94
###begin article-title 95
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.
###end article-title 95
###begin article-title 96
###xml 38 43 <span type="species:ncbi:9606">human</span>
Establishment and characterization of human pancreatic adenocarcinoma cell line SOJ producing carcinoembryonic antigen and carbohydrate antigen 19-9.
###end article-title 96
###begin article-title 97
Cancer-associated thrombosis.
###end article-title 97
###begin article-title 98
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
###xml 35 40 <span type="species:ncbi:9606">human</span>
Thrombogenic activity of mouse and human tumors: effects on platelets, coagulation, and fibrinolysis, and possible significance for metastases.
###end article-title 98
###begin article-title 99
###xml 114 118 <span type="species:ncbi:10090">mice</span>
Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.
###end article-title 99
###begin article-title 100
Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation.
###end article-title 100
###begin article-title 101
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer.
###end article-title 101
###begin article-title 102
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Prevention of venous thromboembolism in cancer patients.
###end article-title 102
###begin article-title 103
Preparing the "soil": the premetastatic niche.
###end article-title 103
###begin article-title 104
Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer.
###end article-title 104
###begin article-title 105
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor.
###end article-title 105
###begin article-title 106
Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.
###end article-title 106
###begin article-title 107
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation.
###end article-title 107
###begin article-title 108
The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression.
###end article-title 108
###begin article-title 109
Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.
###end article-title 109
###begin article-title 110
P-selectin and leukocyte microparticles are associated with venous thrombogenesis.
###end article-title 110
###begin article-title 111
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
###end article-title 111
###begin article-title 112
Plasma fibronectin promotes thrombus growth and stability in injured arterioles.
###end article-title 112
###begin article-title 113
###xml 110 115 <span type="species:ncbi:9606">human</span>
Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts.
###end article-title 113
###begin article-title 114
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 102 108 <span type="species:ncbi:9606">humans</span>
Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans.
###end article-title 114
###begin article-title 115
###xml 7 12 <span type="species:ncbi:10090">mouse</span>
Use of mouse models to study the role of tissue factor in tumor biology.
###end article-title 115
###begin article-title 116
Circulating microparticles: pathophysiology and clinical implications.
###end article-title 116
###begin article-title 117
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.
###end article-title 117
###begin article-title 118
Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor.
###end article-title 118
###begin article-title 119
Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies?
###end article-title 119
###begin article-title 120
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Type 1 and type 2 diabetic patients display different patterns of cellular microparticles.
###end article-title 120
###begin article-title 121
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features.
###end article-title 121
###begin article-title 122
###xml 21 29 <span type="species:ncbi:9606">children</span>
Venous thrombosis in children with solid tumors.
###end article-title 122
###begin article-title 123
Inhibition of platelet function: does it offer a chance of better cancer progression control?
###end article-title 123
###begin article-title 124
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Incidence of venous thromboembolism in patients hospitalized with cancer.
###end article-title 124
###begin article-title 125
Microparticle-associated tissue factor activity: a link between cancer and thrombosis?
###end article-title 125
###begin article-title 126
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients.
###end article-title 126
###begin article-title 127
Phlegmasia alba dolens.
###end article-title 127
###begin article-title 128
Clinique Medicale de l'Hotel-Dieu.
###end article-title 128
###begin article-title 129
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis.
###end article-title 129
###begin article-title 130
Inhibition of tissue factor signaling suppresses tumor growth.
###end article-title 130
###begin article-title 131
Liver Kupffer cells rapidly remove red blood cell-derived vesicles from the circulation by scavenger receptors.
###end article-title 131
###begin article-title 132
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.
###end article-title 132
###begin article-title 133
Cancer-associated thrombosis.
###end article-title 133
###begin p 134
Abbreviations used: MP, microparticle; PPP, platelet-poor plasma; PSGL-1, P-selectin glycoprotein ligand 1; Qdot, quantum dot ; TF, tissue factor.
###end p 134

